Showing results (1391-1400 of 2,232) with videos related to

Sort By:
Pageof 224
Cancer Biotherapy & Radiopharmaceuticals|April 8, 2004
Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancerGiuseppe De Vincentis, Silvia Remediani, Alexandra D Varvarigou, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 8, 2004
New strategies in polypeptide and antibody synthesis: an overviewNico Mertens, Filip Devos, Jannick Leoen, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 8, 2004
Functional-anatomical image fusion in neuroendocrine tumorsOrazio Schillaci
Cancer Biotherapy & Radiopharmaceuticals|January 15, 2005
Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinomaRobert Dillman, Neil Barth, Louis Vandermolen, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 15, 2005
Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomasRobert Dillman, Neil Barth, Senthamil Selvan, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 15, 2005
Preclinical investigations of drug and radionuclide conjugates of bisphosphonates for the treatment of metastatic bone cancerAmal El-Mabhouh, Christo Angelov, Alexander McEwan, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 15, 2005
Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysisRobert Dillman, Senthamil Selvan, Patric Schiltz, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 25, 2005
The evolution of accelerated, partial breast irradiation as a potential treatment option for women with newly diagnosed breast cancer considering breast conservationFrederick M Dirbas, Stefanie S Jeffrey, Don R Goffinet
Cancer Biotherapy & Radiopharmaceuticals|January 25, 2005
The 17th International IRIST Congress ProceedingsChristophe Van de Wiele, Alberto Signore
Cancer Biotherapy & Radiopharmaceuticals|January 25, 2005
Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancerRobert Dillman, Patric Schiltz, Carol DePriest, et al.
Pageof 224